Your browser doesn't support javascript.
[Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir]. / Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir.
Brandariz-Nuñez, David; Correas-Sanahuja, Marcelo; Guarc, Eva; Picón, Rafael; García, Bárbara; Gil, Rocío.
  • Brandariz-Nuñez D; Servicio de Farmacia, Hospital Quironsalud, Barcelona, España. Electronic address: vrandariz@gmail.com.
  • Correas-Sanahuja M; Servicio de Farmacia, Hospital CIMA, Barcelona, España.
  • Guarc E; Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.
  • Picón R; Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.
  • García B; Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.
  • Gil R; Servicio de Farmacia, Hospital Quironsalud, Barcelona, España.
Med Clin (Barc) ; 155(7): 281-287, 2020 10 09.
Article in English, Spanish | MEDLINE | ID: covidwho-688732
ABSTRACT

OBJECTIVES:

To determine the prevalence of potential interactions in COVID-19 patients receiving lopinavir/ritonavir (LPV/r). The secondary objective was to develop recommendations and identify the risk factors associated with presenting potential interactions with LPV/r. SUBJECTS AND

METHODS:

Cross-sectional and multicenter study with the participation of 2 hospitals. COVID-19 patients over 18 years of age, admitted to hospital and under treatment with LPV/r were included. A screening of potential interactions related to LPV/r and home and hospital medication was carried out. Lexicomp® (Uptodate), HIV-drug interactions and COVID-drug interactions were used as the query database.

RESULTS:

361 patients with a mean age of 62.77 ± 14.64 years were included, where 59.6% (n = 215) were men. 62.3% (n = 225) had 1 or more potential interactions and 26, 87% (n = 97) 2 or more. The independent variables associated with presenting ≥1 potential interactions were age (> 65) (OR 1.95; 95% CI 1.06-3.59, P =.033), ICU admission (OR 9.22; CI 95% 1.98-42.93; P =.005), previous respiratory pathology (OR 2.90; 95% CI 1.15-7.36; P =.024), psychiatric (OR 4.14; 95 CI % 1.36-12.61; P =.013), dyslipidemia (OR 3.21; 95% CI 1.63-6.35; P =.001) and the number of drugs prescribed (OR 4.33; 95% CI 2.40-7.81; P =.000).

CONCLUSION:

The prevalence of potential interactions in COVD-19 patient undergoing treatment with LPV/r is high, with age (> 65), ICU admission, previous respiratory and psychiatric pathology, dyslipidemia and the number of prescribed drugs acting as risk factors.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Ritonavir / Lopinavir / Betacoronavirus Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English / Spanish Journal: Med Clin (Barc) Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Coronavirus Infections / Ritonavir / Lopinavir / Betacoronavirus Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English / Spanish Journal: Med Clin (Barc) Year: 2020 Document Type: Article